# CSF2RA

## Overview
The CSF2RA gene encodes the alpha subunit of the granulocyte-macrophage colony-stimulating factor receptor (GM-CSFRα), a critical component of the receptor complex involved in hematopoietic and immune system regulation. This gene is located on the X chromosome and plays a pivotal role in the binding and signaling of granulocyte-macrophage colony-stimulating factor (GM-CSF), a cytokine essential for the proliferation, differentiation, and survival of hematopoietic progenitor cells. The protein encoded by CSF2RA is a transmembrane receptor that, upon binding GM-CSF, forms a heterodimeric complex with the beta subunit, leading to the activation of intracellular signaling pathways such as JAK/STAT, which are crucial for immune responses and inflammation (Martinez-Moczygemba2010Immune; Suzuki2010Hereditary). Mutations in CSF2RA can result in impaired receptor function, contributing to diseases such as pulmonary alveolar proteinosis (PAP), highlighting its clinical significance (Hildebrandt2014Characterization).

## Structure
The CSF2RA gene encodes the alpha subunit of the granulocyte-macrophage colony-stimulating factor (GM-CSF) receptor, which is crucial for GM-CSF signaling. The protein structure includes a signal peptide, an extracellular GM-CSF binding domain, a transmembrane domain, and a cytoplasmic domain (Suzuki2010Hereditary). The extracellular domain is responsible for ligand binding, which is essential for the receptor's function in hematopoiesis (Suzuki2010Hereditary). The CSF2RA protein has 11 N-glycosylation sites, which are common post-translational modifications that can affect protein folding and stability (Suzuki2010Hereditary).

The GM-CSF receptor is a heterodimeric cell-surface receptor composed of the ligand-binding alpha chain (CD116) and an affinity-enhancing beta chain (CD131). Upon ligand binding, the receptor forms active dodecameric signaling complexes, which are necessary for receptor activation and signaling (Martinez-Moczygemba2010Immune). This complex formation involves Janus kinase-2 subunits and activates multiple signaling pathways, including JAK/STAT, Ras/mitogen-activated protein kinase, and PI-3 kinase-Akt pathways (Martinez-Moczygemba2010Immune). The CSF2RA gene can undergo alternative splicing, resulting in different mRNA transcripts that may lead to protein isoforms with distinct functions (Suzuki2010Hereditary).

## Function
The CSF2RA gene encodes the alpha subunit of the granulocyte-macrophage colony-stimulating factor receptor (GM-CSFRα), which is a critical component of the receptor complex for granulocyte-macrophage colony-stimulating factor (GM-CSF). This receptor is a heterodimer, consisting of the CSF2RA subunit and a nonbinding beta subunit, and is essential for the specificity and high-affinity binding of GM-CSF (Suzuki2008Familial; Hetzel2017Function).

In healthy human cells, the binding of GM-CSF to the CSF2RA subunit initiates a signaling cascade involving the phosphorylation of the beta subunit by Janus kinase 2 (JAK2). This activation leads to the phosphorylation of signal transducer and activator of transcription 5 (STAT5), among other pathways, which are crucial for the differentiation and function of alveolar macrophages (Suzuki2008Familial; Hetzel2017Function). These macrophages play a vital role in surfactant catabolism and maintaining pulmonary surfactant homeostasis, which is essential for proper lung function (Suzuki2008Familial; Li2022Gene).

The CSF2RA protein is primarily active on the cell surface, where it binds GM-CSF, triggering intracellular signaling pathways that influence immune responses and inflammation (Hildebrandt2014Characterization). Proper function of this receptor is necessary for the physiological response to GM-CSF, which is important for the function of granulocytes and pulmonary alveolar macrophages (Martinez-Moczygemba2008Pulmonary).

## Clinical Significance
Mutations in the CSF2RA gene are associated with pulmonary alveolar proteinosis (PAP), a rare lung disease characterized by the accumulation of surfactant in the alveoli, leading to respiratory distress and failure. This condition results from impaired granulocyte-macrophage colony-stimulating factor (GM-CSF) signaling, which is crucial for the differentiation and function of alveolar macrophages responsible for surfactant clearance (Hetzel2017Function; Hildebrandt2014Characterization). 

Various mutations in the CSF2RA gene, including missense, nonsense, and frameshift mutations, as well as exon duplications and deletions, have been identified. These mutations can lead to different extents of protein damage, affecting the GM-CSF receptor function and resulting in the clinical manifestations of PAP (Hildebrandt2014Characterization). 

In some cases, whole gene deletions or loss of the C-terminal intracellular domain have been observed, leading to a marked reduction or abolition of GM-CSF-induced STAT5 phosphorylation, a key signaling pathway for surfactant metabolism (Chiu2017WholeGenome; Hildebrandt2014Characterization). 

Gene therapy approaches, such as lentivirus-mediated gene transfer and pulmonary macrophage transplantation, are being explored as potential treatments for CSF2RA-related PAP, offering alternatives to the current invasive treatment of whole lung lavage (Arumugam2019LongTerm; Hetzel2017Function).

## Interactions
The CSF2RA gene encodes the alpha subunit of the granulocyte-macrophage colony-stimulating factor receptor (GM-CSFRα), which is part of a heterodimeric receptor complex essential for GM-CSF signaling. This receptor complex is formed through the interaction of CSF2RA with the beta subunit (CSF2RB), which is shared with receptors for interleukin-3 (IL-3) and interleukin-5 (IL-5) (Hetzel2017Function). The binding of GM-CSF to the CSF2RA subunit initiates the phosphorylation of the beta subunit by Janus kinase 2 (JAK2), leading to the activation of downstream signaling pathways, including the phosphorylation of signal transducer and activator of transcription 5 (STAT5) (Arumugam2019LongTerm; Hetzel2017Function).

Mutations in CSF2RA, such as the G174R mutation, can disrupt its interaction with CSF2RB, impairing GM-CSF receptor signaling and function. This mutation affects the extracellular cytokine binding domain of GM-CSF-Rα, altering a potential glycosylation site necessary for proper receptor function (Suzuki2008Familial). Despite these disruptions, partial receptor signaling can still occur at higher GM-CSF concentrations, indicating that the mutation does not completely eliminate GM-CSF signaling (Suzuki2008Familial).


## References


[1. (Martinez-Moczygemba2008Pulmonary) Margarita Martinez-Moczygemba, Minh L. Doan, Okan Elidemir, Leland L. Fan, Sau Wai Cheung, Jonathan T. Lei, James P. Moore, Ghamartaj Tavana, Lora R. Lewis, Yiming Zhu, Donna M. Muzny, Richard A. Gibbs, and David P. Huston. Pulmonary alveolar proteinosis caused by deletion of the gm-csfrα gene in the x chromosome pseudoautosomal region 1. The Journal of Experimental Medicine, 205(12):2711–2716, October 2008. URL: http://dx.doi.org/10.1084/jem.20080759, doi:10.1084/jem.20080759. This article has 193 citations.](https://doi.org/10.1084/jem.20080759)

[2. (Suzuki2010Hereditary) Takuji Suzuki, Takuro Sakagami, Lisa R. Young, Brenna C. Carey, Robert E. Wood, Maurizio Luisetti, Susan E. Wert, Bruce K. Rubin, Katharine Kevill, Claudia Chalk, Jeffrey A. Whitsett, Carrie Stevens, Lawrence M. Nogee, Ilaria Campo, and Bruce C. Trapnell. Hereditary pulmonary alveolar proteinosis: pathogenesis, presentation, diagnosis, and therapy. American Journal of Respiratory and Critical Care Medicine, 182(10):1292–1304, November 2010. URL: http://dx.doi.org/10.1164/rccm.201002-0271oc, doi:10.1164/rccm.201002-0271oc. This article has 137 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1164/rccm.201002-0271oc)

[3. (Martinez-Moczygemba2010Immune) Margarita Martinez-Moczygemba and David P. Huston. Immune dysregulation in the pathogenesis of pulmonary alveolar proteinosis. Current Allergy and Asthma Reports, 10(5):320–325, July 2010. URL: http://dx.doi.org/10.1007/s11882-010-0134-y, doi:10.1007/s11882-010-0134-y. This article has 17 citations and is from a peer-reviewed journal.](https://doi.org/10.1007/s11882-010-0134-y)

[4. (Li2022Gene) Fengqi Li, Katarzyna Maria Okreglicka, Federica Piattini, Lea Maria Pohlmeier, Christoph Schneider, and Manfred Kopf. Gene therapy of csf2ra deficiency in mouse fetal monocyte precursors restores alveolar macrophage development and function. JCI Insight, April 2022. URL: http://dx.doi.org/10.1172/jci.insight.152271, doi:10.1172/jci.insight.152271. This article has 6 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1172/jci.insight.152271)

[5. (Hetzel2017Function) Miriam Hetzel, Takuji Suzuki, Anna Rafiei Hashtchin, Paritha Arumugam, Brenna Carey, Marc Schwabbauer, Alexandra Kuhn, Johann Meyer, Axel Schambach, Johannes Van Der Loo, Thomas Moritz, Bruce C. Trapnell, and Nico Lachmann. Function and safety of lentivirus-mediated gene transfer forcsf2ra-deficiency. Human Gene Therapy Methods, 28(6):318–329, December 2017. URL: http://dx.doi.org/10.1089/hgtb.2017.092, doi:10.1089/hgtb.2017.092. This article has 16 citations.](https://doi.org/10.1089/hgtb.2017.092)

[6. (Chiu2017WholeGenome) Chih-Yung Chiu, Shih-Chi Su, Wen-Lang Fan, Shen-Hao Lai, Ming-Han Tsai, Shih-Hsiang Chen, Kin-Sun Wong, and Wen-Hung Chung. Whole-genome sequencing of a family with hereditary pulmonary alveolar proteinosis identifies a rare structural variant involving csf2ra/crlf2/il3ra gene disruption. Scientific Reports, February 2017. URL: http://dx.doi.org/10.1038/srep43469, doi:10.1038/srep43469. This article has 11 citations and is from a peer-reviewed journal.](https://doi.org/10.1038/srep43469)

[7. (Hildebrandt2014Characterization) Jenna Hildebrandt, Ebru Yalcin, Hans-Georg Bresser, Guzin Cinel, Monika Gappa, Alireza Haghighi, Nural Kiper, Soheila Khalilzadeh, Karl Reiter, John Sayer, Nicolaus Schwerk, Anke Sibbersen, Sabine Van Daele, Georg Nübling, Peter Lohse, and Matthias Griese. Characterization of csf2ra mutation related juvenile pulmonary alveolar proteinosis. Orphanet Journal of Rare Diseases, November 2014. URL: http://dx.doi.org/10.1186/s13023-014-0171-z, doi:10.1186/s13023-014-0171-z. This article has 57 citations and is from a peer-reviewed journal.](https://doi.org/10.1186/s13023-014-0171-z)

[8. (Suzuki2008Familial) Takuji Suzuki, Takuro Sakagami, Bruce K. Rubin, Lawrence M. Nogee, Robert E. Wood, Sarah L. Zimmerman, Teresa Smolarek, Megan K. Dishop, Susan E. Wert, Jeffrey A. Whitsett, Gregory Grabowski, Brenna C. Carey, Carrie Stevens, Johannes C.M. van der Loo, and Bruce C. Trapnell. Familial pulmonary alveolar proteinosis caused by mutations in csf2ra. The Journal of Experimental Medicine, 205(12):2703–2710, October 2008. URL: http://dx.doi.org/10.1084/jem.20080990, doi:10.1084/jem.20080990. This article has 252 citations.](https://doi.org/10.1084/jem.20080990)

[9. (Arumugam2019LongTerm) Paritha Arumugam, Takuji Suzuki, Kenjiro Shima, Cormac McCarthy, Anthony Sallese, Matthew Wessendarp, Yan Ma, Johann Meyer, Diane Black, Claudia Chalk, Brenna Carey, Nico Lachmann, Thomas Moritz, and Bruce C. Trapnell. Long-term safety and efficacy of gene-pulmonary macrophage transplantation therapy of pap in csf2ra−/− mice. Molecular Therapy, 27(9):1597–1611, September 2019. URL: http://dx.doi.org/10.1016/j.ymthe.2019.06.010, doi:10.1016/j.ymthe.2019.06.010. This article has 23 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1016/j.ymthe.2019.06.010)